|
KMID : 0378019950380070061
|
|
New Medical Journal
1995 Volume.38 No. 7 p.61 ~ p.66
|
|
|
The inhibitory effect on platelet aggregation and safety of triflusal(Disgren^(®))
|
|
|
|
|
Abstract
|
|
|
|
Platelet aggregation plays an important role in the pathogenesis of ischemic stroke, and contributes to the formation of transient ischemic attacks or cerebral infarction. Therefore substances that modify platelet function and inhibit platelet aggregation might be very useful in the prophylaxis and treatment of thromboembolic ischemic disease. Triflusal(Disgrene) is a new platelet aggregation inhibitor structurally related to acetylsalicylic acid(ASA), proven to possess both in vitro and ex vivo platelet antiaggregatory activity. The aims of our study are to determine the effect of Disgren as platelet antiaggregatory agent and to compare the efficacy of Disgren to that of ASA by platelet aggregation test in patients with old cerebral infarction. The platelet aggregation studies are performed by the optical method using platelet rich plasma(PRP). Collagen, ADP, epinephrine and ristocetin are employed as aggregating agents. Disgren at 900mg/day for 8 weeks significantly inhibits platelet aggregation to all aggregating agents. The effect of disgren is superior for platelet antiaggregatory activity to that of ASA employing collagen and epinephrine.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|